Techrat Spółka z Ograniczoną Odpowiedzialnością (KRS 0001033166, NIP 9662176843) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Techrat operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since April 25, 2023.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Techrat
Identity
- Name
- Techrat Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 25, 2023
- Registry status as of
- July 30, 2026
- Latest entry
- July 30, 2026
- Founding act
- 25.04.2023 R.
Articles of association history (2)
- April 25, 2023: 25.04.2023 R.
- March 14, 2026: 14.03.2026 R. ZMIENIONO § 1, § 3, § 5, § 6, § 15
Activities
Other activities
Address and contact
- Address
- UL. KS. PIOTRA WAWRZYNIAKA, 41, 53-022, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-73403-86358-WRRWG-25
Operational status - Techrat
Founded
April 25, 2023
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
N/A
Registry entries
7
latest: July 30, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Techrat.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
